Minimum Target Prices for Production of Direct-Acting Antivirals and Associated Diagnostics to Combat Hepatitis C Virus

Nikolen van de Ven, Joe Fortunak, Bryony Simmons, Nathan Ford, Graham S. Cooke, Saye Khoo, and Andrew Hill

Combinations of direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of treatment-naïve patients. Mass treatment programs to cure HCV in developing countries are only feasible if the costs of treatment and laboratory diagnostics are very low. This analysis aimed to estimate minimum costs of DAA treatment and associated diagnostic monitoring. Clinical trials of HCV DAAs were reviewed to identify combinations with consistently high rates of sustained virological response across hepatitis C genotypes. For each DAA, molecular structures, doses, treatment duration, and components of retrosynthesis were used to estimate costs of large-scale, generic production. Manufacturing costs per gram of DAA were based upon treating at least 5 million patients per year and a 40% margin for formulation. Costs of diagnostic support were estimated based on published minimum prices of genotyping, HCV antigen tests plus full blood count/clinical chemistry tests. Predicted minimum costs for 12-week courses of combination DAAs with the most consistent efficacy results were: US$122 per person for sofosbuvir+daclatasvir; US$152 for sofosbuvir+ribavirin; US$192 for sofosbuvir+ledipasvir; and US$115 for MK-8742+MK-5172. Diagnostic testing costs were estimated at US$90 for genotyping US$34 for two HCV antigen tests and US$22 for two full blood count/clinical chemistry tests.

Conclusions: Minimum costs of treatment and diagnostics to cure hepatitis C virus infection were estimated at US$171-360 per person without genotyping or US$261-450 per person with genotyping. These cost estimates assume that existing large-scale treatment programs can be established. (HEPATOLOGY 2015;61:1174-1182)
with economies of scale. Achieving these low prices is necessary to facilitate treatment scaleup.

The ability to diagnose and monitor HCV simply and inexpensively will be important to ensure widespread access to HCV treatment. At present, because of the limited efficacy and poor tolerability profile of current treatments, HCV diagnosis and monitoring requires a range of complex tests before and during treatment, including genotyping, HCV-RNA quantification by polymerase chain reaction (PCR) assays, and FibroScan to evaluate severity of liver disease. Most resource-limited settings are not equipped to undertake complex laboratory diagnostics at scale. Furthermore, with current treatments, regimen duration and rates of treatment success are highly dependent on the infecting genotype, which varies significantly in its relative prevalence worldwide. Encouragingly, the improved side-effect profile and high SVR rates of new DAAs should allow for simplification of both diagnosis and monitoring of patients and may offer the potential for a standardized package of care of patients.

DAAs for HCV infection have similar chemical structures and mechanisms of action to antiretrovirals (ARVs) used for the treatment of human immunodeficiency virus (HIV) infection. Generic ARVs are currently manufactured at a very low cost, covering treatment for over 10 million people in LMICs. ARV prices have fallen progressively through generic competition, economies of scale from more people treated, and improved efficiencies in procurement of raw materials and production processes for active pharmaceutical ingredients (APIs). Recognizing the limited laboratory infrastructure in resource-limited settings, the public health approach to scaling up access to treatment for HIV has relied on a minimal use of laboratory investigations. In order to replicate the successes of providing widespread ARV therapy, the combined costs of HCV treatment and monitoring will need to be substantially lowered.

Using the cost of HIV drugs as a framework for analysis, we can make estimates for the potential cost of HCV DAAs. This analysis aimed to estimate the minimum costs of DAA treatment considered most promising for large-scale treatment programs in LMICs and associated diagnostic monitoring.

**Materials and Methods**

Clinical trials of HCV DAAs were reviewed to identify combinations with phase II or III trial results, good safety profiles, high SVR rates, a future program of clinical trials in different genotypes, and the potential to reduce treatment duration. Three HCV DAAs—ledipasvir (phase III), MK-8742 (phase III), and MK-5172 (Phase III)—were prioritized for further evaluation based on this review. These DAAs were combined with results from three previously studied drugs: sofosbuvir, daclatasvir, and ribavirin. Table 1 shows summary SVR rates for these combinations of DAAs, based on combining the results of all published trials available.

Based on the chemical synthesis and molecular structure, an approximate range of cost for the API of each DAA was estimated. These calculations assumed an API demand that would cover treatment for 5 million people. Treating 5 million people was considered the starting point for a volume demand large enough to reasonably minimize API prices while assuming cost pressures in the market through competition.

To determine the manufacturing cost, retrosynthetic analysis of each target DAA into its precursor structures and routes of chemical synthesis were taken from the available literature. Additional considerations in assessing the complexity of chemical synthesis included recognizing the cost-limiting intermediates, number of steps of synthesis, and availability/pricing of raw materials.

From the manufacturing cost of an API, a 25% markup as a profit margin for sales with an add-on of 40% for conversion to the finished pharmaceutical product (FPP) was applied to estimate the overall predicted unit cost per person. Estimated API costs for the selected DAAs ranged from US$5,000-7,000 per kg. Because these APIs are relatively expensive at the assumed volume demand, a 40% markup was applied to estimate the cost of the finished dosage form. These assumptions are based on the method previously used to estimate minimum production costs of other DAAs.
Using the daily dose of each DAA identified from clinical trials, the total drug requirement for a 12-week regimen was calculated. With these calculated production costs per gram of DAA together with the total amount of drug required, a minimum cost estimate for a 12-week treatment course of each DAA was calculated. Using these costs and the mid-point estimates for ribavirin, daclatasvir, and sofosbuvir taken from a previous analysis, the production costs of two-drug combination regimens could be estimated based on the combinations currently being studied in clinical trials (Table 1).

Each trial for the chosen DAA combination regimens was studied for treatment-related adverse events. Using the safety profiles from these clinical trials, the minimal necessary tests during treatment were proposed as two full blood count and two clinical chemistry tests, taken before the start of treatment and then at week 4 to monitor ongoing safety issues. Clinical chemistry tests taken before treatment could also be used for simple staging of liver disease (APRI/FIB4) to guide decisions on the duration of DAA treatment.

Using the current literature on the analytical performance characteristics of the available HCV diagnostic tests, it was determined that the lab-based HCV Architect antigen test could be a reasonable alternative in comparison to HCV-RNA PCR for detecting HCV RNA for diagnosis and post-treatment monitoring of HCV patients. In this proposed system, a single antigen test would be performed before the start of treatment to confirm active HCV infection, and then a second antigen test would be performed 6 months after the end of treatment, to confirm that reinfection or relapse had not occurred. Costs of diagnostic support were estimated based on published prices of tests from developing countries.

Using these estimates and the calculated production costs of DAA combination regimens, an overall care package for HCV diagnosis, treatment, and monitoring was calculated.

### Results

The DAAs, sofosbuvir, daclatasvir, ribavirin, ledipasvir, MK-8742, and MK-5172, were considered a priority for the cost analysis. Minimum costs of production of sofosbuvir, daclatasvir, and ribavirin were estimated in a previous analysis, the production costs of two-drug combination regimens could be estimated based on the combinations currently being studied in clinical trials (Table 1).

Each trial for the chosen DAA combination regimens was studied for treatment-related adverse events. Using the safety profiles from these clinical trials, the minimal necessary tests during treatment were proposed as two full blood count and two clinical chemistry tests, taken before the start of treatment and then at week 4 to monitor ongoing safety issues. Clinical chemistry tests taken before treatment could also be used for simple staging of liver disease (APRI/FIB4) to guide decisions on the duration of DAA treatment.

Using the current literature on the analytical performance characteristics of the available HCV diagnostic tests, it was determined that the lab-based HCV Architect antigen test could be a reasonable alternative in comparison to HCV-RNA PCR for detecting HCV RNA for diagnosis and post-treatment monitoring of HCV patients. In this proposed system, a single antigen test would be performed before the start of treatment to confirm active HCV infection, and then a second antigen test would be performed 6 months after the end of treatment, to confirm that reinfection or relapse had not occurred. Costs of diagnostic support were estimated based on published prices of tests from developing countries.

Using these estimates and the calculated production costs of DAA combination regimens, an overall care package for HCV diagnosis, treatment, and monitoring was calculated.

### Table 1. Results From Clinical Trials: Arms Combined, Treatment Naive, by Genotype

| Combination    | Trial                                      | Genotype | Treatment Arms | SVR Rate |
|----------------|--------------------------------------------|----------|----------------|----------|
| Daclatasvir    | Al444-04015 Combined 24wk Arms*            | 1        | 12wk (n = 41)  | 95% (SVR-24) |
|                |                                             | 2 and 3  | 24wk (n = 29)  | 97% (SVR-24) |
| Sofosbuvir     | Combined QUANTUM14 and ELECTRON15,16       | 1        | 12wk (n = 69)  | 75% (SVR-12)  |
|                | Combined POSITRON17 VALENCE,18 FISSION,19 and PHOTON-120 | 2        | 12wk (n = 237) | 94% (SVR-12)  |
|                | Combined POSITRON17 FISSION,18 and PHOTON-120 | 3        | 12wk (n = 323) | 59% (SVR-12)  |
|                | Ruane et al.21                             | 4        | 12wk (n = 14)  | 79% (SVR-12)  |
| Sofosbuvir     | Combined SPARE22 QUANTUM,14 and PHOTON-120 | 1        | 24wk (n = 168) | 73% (SVR-12)  |
|                | VALENCE18                                   | 3        | 24wk (n = 105) | 93% (SVR-12)  |
|                | Ruane et al.21                             | 4        | 24wk (n = 14)  | 100% (SVR-12) |
| Sofosbuvir/ledipasvir | Combined LONESTAR23 and ION-324  | 1        | 8wk (n = 235)  | 94% (SVR-12)  |
|                | Combined LONESTAR23 ION-1,25 ION-3,34 SYNERGY,26 and ERADICATE27 | 12wk (n = 544) | 95% (SVR-12) |
|                | ION-125                                     | 24wk (n = 217) | 97% (SVR-12)  |
|                | ELECTRON-28 Cohort 1                       | 3        | 12wk (n = 25)  | 64% (SVR-12)  |
| MK-8742/MK-5172| C-WORTHY29,31 Combined 12wk arms           | 1        | 12wk (n = 103) | 95% (SVR 4-24) |

*Excluding 12-week regimen for genotype 3.

Abbreviations: wk, week; SVR-4, undetectable hepatitis C virus RNA 4 weeks after finished treatment; SVR-12, undetectable hepatitis C virus RNA 12 weeks after finished treatment; SVR-24, undetectable hepatitis C virus RNA 24 weeks after finished treatment.

**MK-8742.** MK-8742 is a tetracyclic indole-based nonstructural (NS)5A inhibitor with a molecular weight of 882 g/mol. At a 50-mg/day dose, a 12-week course of treatment will require 4.2 g of API. Assuming 5 million patients would be treated, 21 metric tonnes of API would be required. The cost-limiting monobrominated imidazole intermediate (compound 5) and the efficiencies attributed to obtaining chirally pure API at a late stage in the synthesis add substantial expense to the five-step synthesis of MK-8742. The estimated manufacturing cost of MK-8742 FPP is US$10.50/g, based on a nominal API manufacturing cost of US$6,000/kg. At a daily dose of 50 mg, the
estimated production cost for 12 weeks per person-treatment is thus estimated as US$44 per person.

**MK-5172.** MK-5172 is a macrocyclic NS3/4a protease inhibitor with a molecular weight of 767 g/mol and chemical formula of C_{38}H_{50}N_{6}O_{9}S. At a daily dose of 100 mg, 12 weeks of treatment require 8.4 g of API. Assuming 5 million patients would be treated, 42 metric tonnes of API would be required. Compound 2 and 3 are relatively easy to make, and compound 4 is commercially available and therefore cheap. The yields for the most difficult steps of the synthesis—forming the macrocyclicurethane-lactam—are highly efficient. Even though compound 4 is relatively expensive to make, it is incorporated in a high-yielding last step. On 42 metric tonnes of volume demand, the API is estimated to cost US$5,000/kg.
Accordingly, a 12-week treatment with MK-5172 has an estimated cost of US$74 per person.

**Ledipasvir.** Ledipasvir is a NS5A inhibitor with an unsymmetric benzimidazole-difluorofluorene-imidazole core. At a daily dose of 90 mg, a 12-week course of ledipasvir requires 7.6 g of API. This results in an API demand of 38 metric tonnes to treat 5 million patients. Fluorene is the ultimate starting material for this synthesis, with a current price of US$4/kg. Intermediates 4 and 6 for the synthesis of the API are cost-limiting. Overall production costs for the FPP are estimated at US$12.25/g from an API cost of US$7,000/kg, giving an estimated cost per 12-week course of US$93 per person.

**Combination Regimens.** Using the calculated DAA drug prices, the estimated costs of the four most effective combination regimens are shown in Table 3. Previously published cost estimates for ribavirin, sofosbuvir, and daclatasvir were combined with those of the three new DAAs. The 12-week combination of MK-8742 and MK-5172 has an estimated minimum cost of US$118 per person. A 12-week course of daclatasvir or ribavirin and sofosbuvir could cost US$121 or US$149 per person-treatment, respectively. A treatment course combining sofosbuvir and ledipasvir could cost US$129 for 8 week or US$193 for 12 weeks per person. For some patients or some regimens, a 24-week treatment might be necessary, doubling the estimated treatment costs from the 12-week regimen.

**Diagnostic Testing.** The favorable safety profile of these DAA combinations suggests that safety monitoring could be limited to two full blood count plus clinical chemistry tests, including alanine transaminase and creatinine, one pretreatment, and another during treatment.

Results from validation studies indicate a correlation between HCV viral load and antigen quantification, irrespective of HCV genotype, when HCV RNA is >2,000 IU/mL. Compared with HCV RNA, the Architect antigen test was specific, user-friendly, and less expensive. One limitation is the sensitivity, which corresponds to a lower limit of detection (LLOD) of approximately 2,000 IU/mL HCV-RNA levels. Given that the majority of HCV infections and relapsers are associated with a high level of viremia (>2,000 IU/mL), the HCV antigen assay is a robust alternative to HCV-RNA PCR to confirm chronic infection. The reduced sensitivity limits its clinical utility for use during therapy, but could prove to be useful in monitoring patients with virological relapse or reinfection.

Monitoring could involve an HCV antigen test pretreatment to establish infection and a repeat test 6 months after stopping treatment to ensure that reinfection or relapse has not occurred. If treatment is not pangenotypic, HCV genotyping could be added for pretreatment monitoring. Diagnostic testing costs were estimated at US$90 for genotyping, US$34 for two HCV antigen tests, and US$22 for two full blood count and clinical chemistry tests.

**Overall Costs.** The minimum costs of treatment, diagnostic monitoring, and genotyping to cure HCV are shown in Fig. 2. Minimum costs per person range from US$174 for 12 weeks of MK-8742 and MK-5172 with no genotyping to US$444 for 24 weeks of sofosbuvir plus ribavirin with genotyping.

**Discussion**

This analysis suggests that a 12-week IFN-free regimen supported by minimal diagnostic testing could cost US$264-444 per person, if genotyping is required. The use of pangenotypic drugs with no genotyping could cost US$171-360 per person. Recognizing that specialist physician care and advanced laboratory monitoring is not feasible at the scale required to treat large numbers of patients in resource-limited settings, this simplified, easy-to-administer, and tolerable DAA treatment approach would enable HCV to be managed at lower-level health facilities, thereby facilitating widespread treatment access.

### Table 2. Predicted Minimum Costs of Selected HCV DAAs for 12 Weeks of Treatment

| Agent       | Patent Expiry | Daily Dose (mg) | Overall Dose Per 12-wk (g) | Estimated cost/g (US$) | Predicted Cost (US$) |
|-------------|---------------|-----------------|-----------------------------|------------------------|----------------------|
| Ribavirin   | Generic       | 1,200           | 100.8                       | 0.34*                  | $48                  |
| Daclatasvir | 2027          | 60              | 5.0                         | 4.00                   | $20                  |
| MK-8742     | 2028          | 50              | 4.2                         | 10.50                  | $44                  |
| Sofosbuvir  | 2029          | 400             | 33.6                        | 3.00                   | $101                 |
| MK-5172     | 2030          | 100             | 8.4                         | 8.75                   | $74                  |
| Ledipasvir  | 2030          | 90              | 7.6                         | 12.25                  | $93                  |

*Current mid-point cost of API from 3 Chinese suppliers. Abbreviation: wk, week.

### Table 3. Predicted Costs of Key Drug Combinations

| Regimen                  | Daily dose (mg) | Duration (Weeks) | Predicted Unit Cost (US$) |
|--------------------------|-----------------|------------------|---------------------------|
| MK-8742 + MK-5172        | 50 + 100        | 12               | $118                      |
| Daclatasvir + sofosbuvir | 60 + 400        | 12               | $121                      |
| Sofosbuvir + ledipasvir  | 400 + 90        | 8                | $129                      |
| Sofosbuvir + ribavirin   | 400 + 1,200     | 12               | $149                      |

$298
The cost of ARVs in LMICs is mainly driven by the price of the API, which constitutes 65%-90% of the total market price. Through increased volume demand, cheaper raw materials, and improved chemical synthesis, the price of generic antiretroviral APIs has significantly fallen over the last decade. For example, generic manufacture of efavirenz API has fallen from US$1,100 to US$130/kg over this period. This suggests that there is an opportunity for future price reductions for DAA APIs through these same mechanisms. With this in mind, the estimates in this analysis are based on moderate volume demand (5 million people treated per year) and are thus dependent on sizeable procurement orders and the presence of competition in the market as one mechanism to encourage price reductions. There are a number of pricing and procurement mechanisms that need to be utilized in order to secure such orders, and this depends on commitment to improving access to treatment by a range of actors, including originator pharmaceutical companies, generic manufacturers, governments, and donors.

The DAA patent holders (originator companies) are likely to offer treatment to the poorest countries at a discounted price—this is already the case for sofosbuvir. For other countries, the most commonly observed marketing strategies include voluntary licensing agreements to supply medicines to low-income countries, negotiating terms of tiered pricing for middle-income countries, and to maintain standard pricing for those countries considered high-income. However, these strategies are unlikely to stimulate the needed levels of access to those countries most heavily burdened. Patents for these DAAs do not expire until at least 2027, restricting generic production until this time. In order to overcome patents and allow for generic drug production, governments have invoked the Trade-Related Aspects of Intellectual Property Rights (TRIPS) flexibilities to overcome patent barriers and allow generic competition for ARVs and other essential medicines.

Generic competition has been central to the decreasing prices of HIV treatment and has mainly been facilitated by patent opposition in India. Generic drugs are generally considerably cheaper than the originator versions and, furthermore, remain at a constantly low level for LMICs. Another option under the TRIPS flexibilities is employing stricter standards for patentability and opposing new applications. The patent for sofosbuvir has received pregrant opposition on the basis of lack of innovation, which, if approved, will increase competition and help drive down the cost. Such approaches could be employed to increase generic access to other DAAs.

In addition to lowering drug costs, large-scale treatment programs for HIV only became feasible after significant support from international donors, including the establishment of new funding mechanisms. International donors continue to play a significant role in financing the supply of HIV medicines. Owing to the size of the potential orders, large donor organizations also have more bargaining power than individual countries, which will be pivotal in securing lower prices. While international funding for HCV programmes is needed, it is also essential that governments begin to allocate sustained financing for national HCV programs.

The current analysis further suggests that the current diagnostic and monitoring package could be substantially simplified as a result of the improved side-effect...
profile and efficacy of DAA combinations observed in clinical trials. Monitoring with a full blood count plus clinical chemistry test (pretreatment and during treatment) could be sufficient to monitor for side effects and could cost in the region of US$22 per person. If treatment is not pangenotypic, HCV genotyping could be added to pretreatment monitoring. Although qualitative viral load monitoring is desirable and informative, current approaches are expensive and technically complex; this limitation, together with the high SVR rates in current DAA trials, brings into question the necessity of repeated viral load monitoring during treatment. Given that the majority of HCV infections are associated with very high viral loads, including in patients relapsing after treatment, a qualitative HCV antigen test could be sufficient to confirm viral replication or suppression both pre- and post-treatment. The HCV antigen assay is less expensive and requires less technical expertise than PCR assays; further evaluations regarding the LLOD are required. New studies need to assess how often the RNA levels are above the LLOD of 2,000 IU/mL before treatment or at relapse/reinfection and to confirm that the HCV-RNA and HCV antigen tests provide comparable results.

This analysis has several limitations. The results of clinical trials on the new DAAs are not representative of all patient subpopulations in need of treatment. Relatively few patients with genotypes 4-6 have been included in clinical studies, despite these genotypes predominating in certain regions of the world. The high SVR rates for these new DAAs still need to be confirmed in real-world situations outside clinical trials. Most of these DAAs are only at phase III of development or have only recently been approved. Clinical trial populations are selective, and safety in program settings may be different. All regimen cost estimates in this analysis are based on a 12-week treatment course. Shorter treatment durations would further reduce estimated costs if efficacy is shown. Conversely, for some of the currently approved DAA regimens, some genotypes require 24 weeks of treatment. In the future, when clinical trial results are available, the costs of sequences of treatment will be required, including new or existing DAA treatments for patients who relapse on their initial combinations—these costings will need to be included in subsequent analyses. Finally, the estimated costs do not include the importation, transport, and distribution of the drugs.

The HCV pipeline includes several other promising candidates that may emerge as future treatment options. For example the new drug, GS-5816, is clinically active against all genotypes. At a daily dose of 25-100 mg, a 12-week treatment course would only require between 2 and 8 g of API.

In summary, minimum costs of treatment and diagnostics to cure HCV were estimated at US$174-354 per person without genotyping and US$264-444 per person with genotyping. These costs assume that large-scale treatment programs can be established for HCV, similar to those implemented for HIV/acquired immune deficiency syndrome. Treatments with proven pangenotypic activity will be required to avoid expensive pretreatment genotyping, and further reductions in price could be achieved through shorter durations of treatment, if efficacy is proven.

References

1. World Health Organisation. Hepatitis C fact sheet. Updated April 2014. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed May 10, 2014.
2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. HEPATOLOGY 2013;57:1333-1342.
3. Londeix P, Forette C. New treatments for hepatitis C virus: strategies for achieving universal access. Médecins du Monde. 2014. Available at: http://www.hepcollaboration.org/IMG/pdf/daa_strategies_for_achieving_universal_access_en.pdf. Accessed May 10, 2014.
4. Hagan LM, Sulkowski MS, Schinazi RF. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/ribavirin/simeprevir for genotype 1 hepatitis C virus in interferon-intolerant/insufficient individuals. HEPATOLOGY 2014;60:37-45.
5. Hill A, Khoo S, Fortunak J, Simmons B, Ford N. Minimum costs for producing hepatitis C direct acting antivirals, for use in large-scale treatment access programs in developing countries. Clin Infect Dis 2014;58:928-936.
6. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis c virus infection. HEPATOLOGY 2014;60:392-420.
7. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. HEPATOLOGY 2014 Jul 28. doi: 10.1002/hep.27259. [Epub ahead of print].
8. Médecins Sans Frontieres Access Campaign. Diagnosis and treatment of hepatitis C: a technical overview. Médecins Sans Frontieres. 2014. Available at: http://www.msfaccess.org/sites/default/files/MSF_assets/HepC/Docs/HepC_Report_DxTxTech_23OCT2013.pdf. Accessed May 20, 2014.
9. Callaway E. Hepatitis C drugs not reaching poor. Nature 2014;508:295-296.
10. UNITAID. HIV medicines technology and market landscape. UNITAID and World Health Organisation. 2014. Available at: http://www.unitaid.eu/images/marketedynamics/publications/HIV-Meds-Landscape-March2014.pdf. Accessed May 17, 2014.
11. Hill A, Cooke G. Hepatitis C can be cured globally, but at what cost? Science 2014;345:141-142.
12. The Lancet. Only just the beginning of the end of hepatitis C. Lancet 2014;383:281.
13. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-221.
14. Tice JA, Ollendorf DA, Pearson SD. The comparative clinical effective-
ness and value of simeprevir and sofosbuvir in the treatment of chronic hepatitis C infection. Institute for Clinical and Economic Review. 2014. Available at: http://ctaf.org/sites/default/files/assessments/CTAF_ Hep_C_April14_final.pdf. Accessed May 20, 2014.

15. Gane EJ, Stedman CA, Hyland RH, Soremekun RD, Symonds WT, Hindes R, et al. Once daily sofosbuvir (GS-7977) plus ribavirin in patients with HCV genotypes 1, 2, and 3: The ELECTRON Trial. Paper presented at the 63rd Annual Meeting of the American Association for the Study of the Liver Diseases (AASLD), November 9-13, 2012, Boston, MA. Abstract 229.

16. Gane EJ, Stedman CA, Hyland RH, Ding X, Pang PS, Symonds WT, et al. ELECTRON: all-oral sofosbuvir-based 12-week regimens for the treatment of chronic HCV GT 1 infection. Paper presented at the 49th Annual Meeting of the European Association for the Study of Liver Disease (EASL), April 24-28, 2013, Amsterdam, The Netherlands. Abstract 14.

17. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-1877.

18. Zeuzem S, Dusheiko GM, Lupuere R, Mangia A, Flisiak R, Hyland RH, et al. GS-7977 and ribavirin in treatment naïve and treatment experienced subjects with chronic genotype 2 or 3 HCV infection. Paper presented at the 64th Annual Meeting of the American Association for the Study of the Liver Diseases (AASLD), November 1-5, 2013, Washington, DC. Abstract 1085.

19. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-1887.

20. Zeeuwen S, Dusheiko GM, Lupuere R, Mangia A, Flisiak R, Hyland RH, et al. GS-7977 and ribavirin in treatment naïve and treatment experienced subjects with chronic genotype 2 or 3 HCV infection. Paper presented at the 59th Annual Meeting of the European Association for the Study of Liver Disease (EASLD), November 1-5, 2013, Washington, DC. Abstract 26.

21. Ruane PJ, Ain D, Medscrevey R, Riad J, Stryker R, Soliman M, et al. Sofosbuvir plus ribavirin, an interferon-free regimen, in the treatment of treatment-naïve and treatment-experienced patients with chronic genotype 4 HCV infection. Paper presented at the 49th Annual Meeting of the European Association for the Study of the Liver (EASL), April 9-13, 2014, London, UK. Abstract P1243.

22. Osinusi A, Reissner EG, Bon D, Lee YJ, Proesch M, Hermann E, et al. High efficacy of sofosbuvir in combination with weight based ribavirin for 24 weeks in difficult to treat HCV infected genotype-1 patients. Paper presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI), March 3-6, 2013, Boston, MA. Abstract 26.

23. Lawitz E, Poordad FF, Pang PS, Hyland RH, Mo H, Symonds WT, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naïve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014;383:515-523.

24. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, An D, et al. Ledipasvir/sofosbuvir with and without ribavirin for 8 weeks compared to ledipasvir/sofosbuvir for 12 weeks in treatment naïve non-cirrhotic genotype-1 HCV-infected patients: the phase 3 ION-3 study. Paper presented at the 49th Annual Meeting of the European Association for the Study of the Liver (EASL), April 9-13, 2014, London, UK. Abstract O56.

25. Mangia A, Marcellin P, Kwo P, Foster GR, Buti M, Braun N, et al. All oral fixed-dose combination sofosbuvir/ledipasvir with or without ribavirin for 12 or 24 weeks in treatment-naïve genotype 1 HCV-infected patients: the phase 3 ION-1 study. Paper presented at the 49th Annual Meeting of the European Association for the Study of the Liver (EASL), April 9-13, 2014, London, UK. Abstract O164.

26. Kohli A, Sims Z, Marti M, Nelson A, Osinusi A, Bon D, et al. Combination oral hepatitis C antiviral therapy for 6 or 12 weeks: final results of the SYNERGY trial. Paper presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI), March 3-6, 2014, Boston, MA. Abstract 27-LB.

27. Osinusi A, Townsend K, Nelson A, Kohli A, Gross C, Polis MA, et al. Use of sofosbuvir/ledipasvir fixed dose combination for treatment of HCV genotype-1 in patients coinfected with HIV. Paper presented at the 49th Annual Meeting of the European Association for the Study of the Liver (EASL), April 9-13, 2014, London, UK. Abstract O14.

28. Gane EJ, Hyland RH, An D, Pang PS, Symonds WT, McChuskiton JG, et al. Sofosbuvir/ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients, and genotype-1 patients with prior sofosbuvir treatment experience. Paper presented at the 49th Annual Meeting of the European Association for the Study of the Liver (EASL), April 9-13, 2014, London, UK. Abstract O6.

29. Hezode C, Serfaty L, Vielrling JM, Kugelmans M, Perlman B, Sievert W, et al. Safety and efficacy of the all-oral regimen of MK-5172/MK-8742 ± ribavirin in treatment-naïve, non-cirrhotic, patients with hepatitis C virus genotype 1 infection: the C-WORTHY study. Paper presented at the 49th Annual Meeting of the European Association for the Study of the Liver (EASL), April 9-13, 2014, London, UK. Abstract O10.

30. Lawitz E, Hezode C, Gane E, Tam E, Lagging M, Balart L, et al. Efficacy and safety of MK-5172 and MK-8742 ± ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null-response: the C-WORTHY study. Paper presented at the 49th Annual Meeting of the European Association for the Study of the Liver (EASL), April 9-13, 2014, London, UK. Abstract O61.

31. Sulkowski M, Malledas J, Pol S, Gertoff J, Shibolet O, Nahass R, et al. Efficacy and safety of the all-oral regimen, MK-5172/MK-8742 +/- RBV for 12 weeks in GT1 HCV/HIV co-infected patients: the C-WORTHY study. Paper presented at the 49th Annual Meeting of the European Association for the Study of the Liver (EASL), April 9-13, 2014, London, UK. Abstract O63.

32. National Health Laboratory Service. State pricing list 2012-2013. Available at: http://www.nhls.ac.za/. Accessed May 3, 2014.

33. Lawitz E, Hezode C, Serfaty L, Vielrling JM, Kugelmans M, Perlman B, Sievert W, et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem 2013;8:1930-1940.

34. Harper S, McCauley RA, Rudd MT, Ferrara M, DiFilippo M, Crescenzi B, et al. Discovery of MK-5172, a macrocytic hepatitis C virus NS5A/4 protease inhibitor. ACS Med Chem Lett 2012;3:322-326.

35. Kato A, Kato J, Zhong YL, Yazu N, Beutner G, Lin H, Kim M, et al. Development of a practical asymmetric synthesis of the hepatitis C virus protease inhibitor MK-5172. Org Lett 2013:15: 4174-4177.

36. Link JO, Taylor JG, Xu L, Mitchell M, Guo H, Liu H, et al. Discovery of ledipasvir (GS-5885): a potent, once-daily oral NSSA inhibitor for the treatment of hepatitis C virus infection. J Med Chem 2014;57: 2033-2046.

37. Morota K, Fujiinami R, Kinukawa H, Machida T, Ohko N, Sagoa H, et al. A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen. J Virol Methods 2009;157:8-14.

38. Dormishen J, Sussler S, Berger A, Perner D, Pfiffner KH, Allwin R, et al. Clinical utility of the ARCHITECT HCV Ag assay for early screening on laboratory tests with clinical hepatitis C genotype 1. J Clin Virol 2012;55: 17-22.

39. Gupta E, Bajpai M, Choudhary A. Hepatitis C virus: screening, diagnosis, and interpretation of laboratory assays. Asian J Transfus Sci 2011;5:2033-2046.

40. Kato A, Kato J, Zhong YL, Yazu N, Beutner G, Lin H, Kim M, et al. Development of a practical asymmetric synthesis of the hepatitis C virus protease inhibitor MK-5172. Org Lett 2013:15: 4174-4177.
42. Ciotto M, D’Agostini C, Marrone A. Advances in the diagnosis and monitoring of hepatitis C virus infection. Gastroenterol Res 2013;6:161-170.
43. Hosseini-Moghaddam SM, Iran-Parviz E, Roststein C, Husain S, Lilly L, Renner E, et al. Hepatitis C core Ag and its clinical applicability: potential advantages and disadvantages for diagnosis and follow-up? Rev Med Virol 2012;22:156-165.
44. Miedouge M, Saune K, Kamar N, Rieu M, Rostaing L, Izopet J. Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. J Clin Virol 2010;48:18-21.
45. Bhagani S. A hepatitis C virus core antigen assay is a cost-effective, sensitive and specific test in the detection of acute hepatitis C in HIV infection. Presented at the 3rd Joint Conference of the British HIV Association (BHIVA) and British Association for Sexual Health and HIV (BASHH), April 1-4, 2014, Liverpool, UK. Abstract O22.
46. Park Y, Lee JH, Kim BS, Kim DY, Han KH, Kim HS. New automated hepatitis C virus (HCV) core antigen assay as an alternative to real-time PCR for HCV RNA quantification. J Clin Microbiol 2010;48:2253-2256.
47. Hill A, Khoo S, Simmons B, Ford N. What is the minimum cost per person to cure HCV? Poster presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 1-5, 2013, Washington, DC. Poster 1097.
48. Anilkumar GN, Rosenblum SB, Venkatraman S, Njoroge FG, Kozlowski JA. 2,3-substituted azaindole derivatives for treating viral infections. US8404845 (patent). 2013. Available at: http://www.google.com/patents/US8404845. Accessed May 22, 2014.
49. Harper S, Liveron NJ, McAuley JA, Summa V. Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors. US8080654 (patent). 2011. Available at: http://www.google.com/patents/US8080654. Accessed May 23, 2014.
50. Gilead Sciences Inc. Form 10-K: annual report pursuant to section 13 or 15(d) of the securities exchange act of 1934. Fiscal year ending Dec 31, 2012. Page 17. 2013. Available at: http://www.sec.gov/Archives/edgar/data/882095/000088209513000015/a2012form10-k.htm. Accessed May 24, 2014.
51. New W. Rich and poor countries divided on patent treaty. Bulletin of the WHO. 2006;84:337-424.
52. Médecins Sans Frontières Access Campaign. Untangling the web of antiretroviral price reductions. Médecins Sans Frontières. 2013. Available at: www.msfaccess.org/content/untangling-web-antiretroviral-price-reductions-16th-edition. Accessed May 11, 2014.